Scott T. Reents - Jun 28, 2022 Form 3 Insider Report for AbbVie Inc. (ABBV)

Role: SVP, Chief Financial Officer
Signature: Steven L. Scrogham, attorney-in-fact for Scott T. Reents
Stock symbol: ABBV
Transactions as of: Jun 28, 2022
Transactions value $: $0
Form type: 3
Date filed: 7/8/2022, 01:11 PM
Next filing: Feb 21, 2023

Transactions Table

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Ownership	Footnotes
holding	ABBV	Common Stock, $0.01 par value						809	Jun 28, 2022	Direct

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Underlying Class	Amount	Exercise Price	Ownership	Footnotes
holding	ABBV	Option (Right to buy)							Jun 28, 2022	Common Stock	14.1K	$61.36	Direct	F1
holding	ABBV	Option (Right to buy)							Jun 28, 2022	Common Stock	11.8K	$114.36	Direct	F2
holding	ABBV	Option (Right to buy)							Jun 28, 2022	Common Stock	19.5K	$79.02	Direct	F3
holding	ABBV	Option (Right to buy)							Jun 28, 2022	Common Stock	28.6K	$93.50	Direct	F4
holding	ABBV	Option (Right to buy)							Jun 28, 2022	Common Stock	15.5K	$105.92	Direct	F5
holding	ABBV	Option (Right to buy)							Jun 28, 2022	Common Stock	11.4K	$144.54	Direct	F6

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	Employee stock option granted pursuant to the AbbVie 2013 Incentive Stock Program in a transaction exempt from Section 16 under Rule 16b-3. The option became exercisable as to 4,714 shares on 2/16/2018, as to 4,713 shares on 2/16/2019 and as to 4,713 shares on 2/16/2020.
F2	Employee stock option granted pursuant to the AbbVie 2013 Incentive Stock Program in a transaction exempt from Section 16 under Rule 16b-3. The option became exercisable as to 3,936 shares on 2/15/2019, as to 3,937 shares on 2/15/2020 and as to 3,937 shares on 2/15/2021.
F3	Employee stock option granted pursuant to the AbbVie 2013 Incentive Stock Program in a transaction exempt from Section 16 under Rule 16b-3. The option became exercisable as to 6,490 shares on 2/21/2020, as to 6,490 shares on 2/21/2021 and as to 6,490 shares on 2/21/2022.
F4	Employee stock option granted pursuant to the AbbVie 2013 Incentive Stock Program in a transaction exempt from Section 16 under Rule 16b-3. The option became exercisable as to 9,547 shares on 2/20/2021, as to 9,547 shares on 2/20/2022 and will become exercisable as to 9,547 shares on 2/20/2023.
F5	Employee stock option granted pursuant to the AbbVie Amended and Restated 2013 Incentive Stock Program in a transaction exempt from Section 16 under Rule 16b-3. The option became exercisable as to 5,176 shares on 2/18/2022, and will become exercisable as to 5,176 shares on 2/18/2023 and as to 5,175 shares on 2/18/2024.
F6	Employee stock option granted pursuant to the AbbVie Amended and Restated 2013 Incentive Stock Program in a transaction exempt from Section 16 under Rule 16b-3. The option will become exercisable as to 3,794 shares on 2/17/2023, as to 3,794 shares on 2/17/2024 and as to 3,795 shares on 2/17/2025.